1-A-46

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug Name1-A-46
Drug Alias Name1A461-A-46CMG1A46CMG1A-46BR110 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3Anti-CD19Anti-CD20
TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsLupus Erythematosus, SystemicLymphoma, B-CellLymphoma, Non-Hodgkin +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland ChinaJapan
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChengdu Chimagen Biosciences Co LtdHisun Biopharmaceutical Co LtdZhejiang BioRay Biopharmaceuticals Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGlaxosmithkline PlcZhejiang BioRay Biopharmaceuticals Co LtdChengdu Chimagen Biosciences Co Ltd +[4] 
Inactive CompaniesBioRay Pharmaceutical Co Ltd
Active IndicationsLupus Erythematosus, SystemicLymphoma, Non-Hodgkin
Inactive IndicationsLymphoma, B-CellNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A